Intellia Therapeutics announced its strategic priorities and key anticipated milestones for 2025. However, investors were ...

Moderna provides updates on its business and pipeline progress at the J.P. Morgan Healthcare Conference.

Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Sage Therapeutics’ shares jumped over 45% to $8.09 in after-hours on Friday, after the company confirmed that biotech major ...

In sum, Truist says stick with the longer-term stock uptrend, and any investors who are underweight their target equity position should use the pullback to buy over time. The U.S. is Truist's ...

How is the scent of Tasmania likely to be received when Malano ultimately produces its aromatic homage to the island state?

Nvidia pushes back on new artificial-intelligence regulations, Tesla stock trades lower, and Intra-Cellular Therapies is ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned a consensus rating of “Hold” from the ...

Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.